Background and aim To evaluate the prevalence of subclinical cardiovascular (CV) abnormalities in systemic lupus erythematosus (SLE) stratified according to SLE-related organ damage using the Systemic Lupus International Collaborating Clinics (SLICC) damage index. Methods and results We selected SLE patients without clinically overt CV events (n = 45, 56% with SLICC = 0, 44% with SLICC = 1–4). CV evaluation was performed using cardiac and vascular echo-Doppler techniques. Post-ischemic flow-mediated dilation (FMD) over nitroglycerine-mediated dilation (NMD) of the brachial artery <0.70 defined endothelial dysfunction. The prevalence of preclinical CV abnormalities (CVAbn, including at least one of the following—carotid atherosclerosis, left ventricular (LV) hypertrophy, low arterial compliance, LV wall motion abnormalities, aortic regurgitation, FMD/NMD < 0.70)—was 64% (16/25) in patients with SLICC = 0 and 80% (16/20) in those with SLICC > 0 (p = not significant (NS)). In particular, the prevalence of carotid atherosclerosis (28% vs. 16%), of LV hypertrophy (12% vs. 6%) and of LV wall motion abnormalities (15% vs. 12%), of low global arterial compliance (18% vs. 10%), prevalence of aortic regurgitation (30% vs. 18%) and/or aortic valve fibrosclerosis (10% vs. 8%), FMD < 10% (14 ± 5% vs. 14% ± 6) and prevalence of FMD/NMD < 0.70 (53% vs. 52%) were comparable in SLE patients with SLICC > 0 and in those with SLICC = 0 (all p = NS). Of the SLE patients without carotid atherosclerosis, LV hypertrophy, low arterial compliance, LV wall motion abnormalities and aortic regurgitation (n = 17), endothelial dysfunction was detected in 50% of those with SLICC = 0 (6/12) and in 40% of those with SLICC > 0 (2/5, p = NS). Conclusions SLE patients with SLICC = 0 often have an elevated CV risk profile due to subclinical manifestations of CV disease detectable by cardiac and vascular echo-Doppler evaluations.

High prevalence of subclinical cardiovascular abnormalities in patients with systemic lupus erythematosus in spite of a very low clinical damage index

VALENTINI, Gabriele;
2009

Abstract

Background and aim To evaluate the prevalence of subclinical cardiovascular (CV) abnormalities in systemic lupus erythematosus (SLE) stratified according to SLE-related organ damage using the Systemic Lupus International Collaborating Clinics (SLICC) damage index. Methods and results We selected SLE patients without clinically overt CV events (n = 45, 56% with SLICC = 0, 44% with SLICC = 1–4). CV evaluation was performed using cardiac and vascular echo-Doppler techniques. Post-ischemic flow-mediated dilation (FMD) over nitroglycerine-mediated dilation (NMD) of the brachial artery <0.70 defined endothelial dysfunction. The prevalence of preclinical CV abnormalities (CVAbn, including at least one of the following—carotid atherosclerosis, left ventricular (LV) hypertrophy, low arterial compliance, LV wall motion abnormalities, aortic regurgitation, FMD/NMD < 0.70)—was 64% (16/25) in patients with SLICC = 0 and 80% (16/20) in those with SLICC > 0 (p = not significant (NS)). In particular, the prevalence of carotid atherosclerosis (28% vs. 16%), of LV hypertrophy (12% vs. 6%) and of LV wall motion abnormalities (15% vs. 12%), of low global arterial compliance (18% vs. 10%), prevalence of aortic regurgitation (30% vs. 18%) and/or aortic valve fibrosclerosis (10% vs. 8%), FMD < 10% (14 ± 5% vs. 14% ± 6) and prevalence of FMD/NMD < 0.70 (53% vs. 52%) were comparable in SLE patients with SLICC > 0 and in those with SLICC = 0 (all p = NS). Of the SLE patients without carotid atherosclerosis, LV hypertrophy, low arterial compliance, LV wall motion abnormalities and aortic regurgitation (n = 17), endothelial dysfunction was detected in 50% of those with SLICC = 0 (6/12) and in 40% of those with SLICC > 0 (2/5, p = NS). Conclusions SLE patients with SLICC = 0 often have an elevated CV risk profile due to subclinical manifestations of CV disease detectable by cardiac and vascular echo-Doppler evaluations.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11591/191198
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 26
social impact